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Objectives:  The  present  study  assessed  the  predictive  value  of  [18F]-FDG  PET-CT  (positron  emission
tomography  with  18-ﬂuoro-eoxyglucose  radiotracer,  coupled  to  computerized  tomography)  for  response
to induction  chemotherapy  in  head  and  neck squamous  cell  carcinoma  (HNSCC).
Material and  methods:  [18F]-FDG  PET-CT  was  systematically  performed  before  treatment  initiation  and
after  the  ﬁrst  cycle  of  chemotherapy.  Results  were  compared  with  those  of endoscopy  and  pathologic
analysis  of  biopsy  and  surgical  specimens.
Results:  This  preliminary  study  included  21 previously  untreated  HNSCC  patients.  A  decrease  of  more  than
30% in  SUVmax  (maximum  standard  uptake  value)  during  induction  was  predictive  of tumor  response
to  chemotherapy  (P = 0.04).  PET-CT  measurement  of  hypermetabolic  volume  based  on  a predetermined
SUV  threshold  (SUV  =  2.5),  on  the  other  hand,  proved  non-predictive.
Conclusion:  These  preliminary  ﬁndings  are  promising.  A larger  sample,  however,  would  be  required  in
order  to determine  a  more  precise  SUVmax  reduction  cut-off  threshold  during  induction.  Other  meth-
ods  for determining  metabolic  volume  thresholds  will be  investigated.  If functional  imaging  proves
contributive,  it could  enable  early  screening  of non-responders,  avoiding  unnecessary  intoxication.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
The role of induction chemotherapy in the management of
dvanced head and neck squamous cell carcinoma (HNSCC)
emains a matter of debate. Although some studies reported no
eneﬁt in terms of survival [1,2], it is generally agreed to be use-
ul in organ-sparing strategies and improving quality of life [3,4].
esponse to induction chemotherapy has even been reported to be
redictive of radiation therapy response, and complete response to
e predictive of disease control [5,6].
Even so, it is principally recommended in advanced HNSCC, with
ariable results; only 70% of laryngeal and hypopharyngeal tumors
re chemosensitive [5,6]. It would therefore be useful to be able to
istinguish responder and non-responder subgroups. To that end,
∗ Corresponding author. Service d’oto-rhino-laryngologie et de chirurgie cervico-
aciale, CHU de Saint-Étienne, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez,
rance.
E-mail address: marie.gavid@chu-st-etienne.fr (M.  Gavid).
http://dx.doi.org/10.1016/j.anorl.2014.01.009
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.early identiﬁcation of responders and close surveillance of patients
receiving this organ-sparing treatment need to be improved.
The role in this context of metabolic functional imaging by
[18F]-FDG PET-CT (positron emission tomography with 18-ﬂuoro-
eoxyglucose radiotracer, coupled to computerized tomography)
is currently under assessment. In isolated cervical adenopathy,
it has been shown to be effective in locating the primary tumor
and detecting metastasis, and for post-treatment surveillance and
screening for synchronous tumor in these high-risk patients [7,8].
It has also been shown to be predictive of tumor reduction under
chemotherapy and of survival in esophageal and gastric carcinoma
and soft-tissue sarcoma [9–11]. These various studies demon-
strated that a reduction in tumoral metabolic activity exceeding
30–35% on PET-CT was  predictive of both tumor chemosensitivity
and survival [9–11].
The present study assessed the predictive value of PET-CT for
tumor response to induction chemotherapy in locally advanced
HNSCC. Reduction in SUVmax (maximum standard uptake value)
and in hypermetabolic tumor volume between 2 sessions of func-
tional imaging were analyzed.
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Mean initial SUVmax was 17.98 ± 3.31 in responders, versus
15.93 ± 6.22 in non-responders (P = 0.3).
Responders showed a signiﬁcantly greater mean SUVmax
reduction between PET-CT examinations: 46.3 ± 25.03% (Fig. 2),
Table 1
Population data.
n % Mean ± SD
Gender
Male 18 86
Female 3 14
Age at diagnosis (years) 56.8 ± 7.12
Location
Piriform sinus 15 71
Oropharynx 6 29
TNM stageFig. 1. Thera
. Material and method
.1. General principle
This preliminary study assessed the correlation between reduc-
ion in SUVmax and in hypermetabolic tumor volume following a
rst cycle of induction chemotherapy on the one hand, and clini-
al response at end of therapy on the other. Two [18F]-FDG PET-CT
xaminations were systematically performed: one prior to initia-
ion and one between the ﬁrst two cycles (Fig. 1).
.2. Inclusion criteria and initial assessment
This retrospective preliminary study included patients with
reviously untreated, locally advanced stage III or IV HNSCC, eli-
ible for organ-sparing treatment, between November 2010 and
ovember 2012. Initial assessment comprised [18F]-FDG PET-CT,
anendoscopy of the head and neck, and biopsies for pathologic
nalysis. PET-CT systematically preceded biopsy, so as to focus
ampling on suspect regions and avoid the false positives incurred
y subsequent inﬂammation.
.3. Therapeutic principle
Patients received 2 or 3 cycles, according to tolerance, of
PF: docetaxel 60 mg/m2, cisplatin 75 mg/m2 and 5FU 750 mg/m2
5,6]. Four or ﬁve weeks after the end of induction ther-
py, clinical response was assessed on endoscopy. Individual
reatment continuation by radiochemotherapy or surgery was dis-
ussed in multidisciplinary team meeting, depending on clinical
esponse, induction chemotherapy being considered effective for
esponse ≥ 70%.
.4. PET-CT examination and interpretation
[18F]-FDG PET-CT was systematically performed on the Biograph
®LSO PICO 3D PET/CT HI-REZ system (Siemens Medical, Knoxville,
N, USA), in the nuclear medicine department. 18-FDG (4 MBq/kg)
as administered intravenously, under fasting and glycemic equi-
ibrium (assessed by capillary glycemia). Images were acquired in
 steps, 1 hour after injection:
high-resolution head and neck acquisition comprised CT with-
out contrast enhancement (85 mAs; 130 kV; slice thickness,
3 mm;  pitch, 0.85; caredose) followed by 2 16.2-cm PET steps
of 10 minutes each, with arms along the body;
thoracic-abdominal-pelvic acquisition comprised CT without
contrast enhancement (52 mAs; 130 kV; slice thickness, 5 mm;
pitch, 1.5; caredose) followed by 7 or 8 16.2-cm PET steps of
6 minutes each, with arms behind the head.A dedicated post-treatment console (Leonardo; Siemens) was
sed for image reading and processing. CT was used for anatomic
orrelation and to correct PET-image attenuation. For interpreta-
ion, the head was realigned along the axis of the hard palate. ﬂow-chart.
All lymph-node, visceral and bone lesions showing visual hyper-
ﬁxation beyond the physiological ﬁxation were considered suspect.
For each suspect lesion, two values were assessed:
• maximum standardized uptake value (SUVmax): maximal
metabolism in a region of interest (ROI), quantifying 18-FDG
uptake in target tissue. ROI SUV was  calculated as: SUV = tissue
radioactivity [Bq/kg]/(injected dose [Bq]/body weight [kg]).
SUVmax assesses metabolic intensity;
• metabolic volume: volume measured from isocontours of
SUV = 2.5, with pixels within the ROI around the tumor showing
SUV > 2.5 included in the target.
2.5. Statistics
The contribution of PET-CT was  assessed by comparing reduc-
tions in SUVmax and hypermetabolic volume in chemotherapy
responders versus non-responders on Mann-Whitney U-test. The
signiﬁcance threshold was  set at P < 0.05.
3. Results
Twenty-one patients were included between 2010 and 2012.
Mean age at diagnosis was 56.8 ± 7.1 years (range, 48–67 years),
with a sex ratio of 14% female to 86% male. Seventy-one per-
cent (n = 15) presented with piriform sinus tumor and 29% with
oropharyngeal carcinoma; there were 12 stage T3 and 9 stage
T4 carcinomas. Ninety-ﬁve percent of patients showed signiﬁcant
lymph-node involvement: stage N2 or N3 (Table 1).
Two patients underwent only 1 cycle of chemotherapy, due to
onset of infarction and unstable angina.
In 62% (n = 13) of the 21 patients, the neoadjuvant chemotherapy
was considered effective, with ≥ 70% tumor reduction on control
endoscopy of the upper aerodigestive tract at end of induction
(Table 2). The mean interval between ﬁrst chemotherapy cycle and
second PET-CT examination was 15.6 ± 5.4 days.T3 12 57
T4 9 43
N0–N1 1 5
N2–N3 20 95
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Table  2
SUV and metabolic volume.
Number of
cyclesa
Result after
chemotherapyb
SUVmax on 1st
PET-CTc
SUVmax on
2nd PET-CTd
Hypermetabolic
volume on 1st PET-CTe
Hypermetabolic volume
on 2nd PET-CT
2 60% 12 7.86 105 14
1  50% 22.3 18.3 178 47
2  50% 25.5 20.1 206 88
2  60% 20.7 17.4 215 92
1  50% 13.5 8.5 108 86
2  0% 10.8 9.5 47 73
2  10% 15 9.75 210 111
2  50% 7.7 7.8 10 10
2  100% 21.5 7 58 23
3  70% 18.5 15.5 56 56
2  70% 20 8.5 35 19
2  95% 16.8 14 111 68
2  100% 18.6 7.11 14 6.41
2  90% 17.3 11.6 43 33
2  80% 12.5 6.4 41 18
2  100% 18.7 3.1 87 0.027
2  100% 17 8.5 141 32
3  70% 26 6 41 8
2  100% 15.5 11.8 57 26
2  70% 15.7 5.3 23 9
2  75% 15.6 15.6 101 126
a Number of chemotherapy cycles: docetaxel, 5FU, cisplatin.
b Clinical results on panendoscopy under general anesthesia.
v
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a
t
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lc PET-CT prior to 1st chemotherapy cycle.
d PET-CT after 1st chemotherapy cycle.
e Volume (cm2) of hypermetabolic region on PET-CT.
ersus 21.6 ± 12.9% in non-responders (Fig. 3) (P = 0.04). PET-CT
recision for a 30% SUVmax reduction threshold during chemother-
py was thus 0.67, with a positive predictive value of 0.75.
Non-responders tended to show greater reduction in hyperme-
abolic volume than responders, but without signiﬁcant difference:
0.1 ± 28.2 and 42.7 ± 32.5, respectively (P > 0.05) (Table 3).
In accordance with the treatment protocol, non-responders
nderwent surgery. Pathologic examination of operative and
ymph-node dissection specimens systematically conﬁrmed the
Fig. 2. PET-CT in a responder todiagnosis of HNSCC. In contrast, pathologic analysis of biopsy sam-
ples from patients free of tumor at the end of chemotherapy (i.e.,
with 100% response) found no residual HNSCC.
4. DiscussionAssessing response to induction chemotherapy is a major issue
in the treatment and prognosis of advanced head and neck squa-
mous cell carcinoma [2,4]. Consensual criteria are morphological,
 induction chemotherapy.
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ased on endoscopy and CT or MRI. CT and MRI  assessment of tumor
olume reduction on the RECIST system (Response Evaluation
riteria in Solid Tumors), however, is complicated by inﬂamma-
ion and tumoral necrosis. Tumor volume assessed on imaging
hows large inter-observer variation [12,13], and imaging is of
o early predictive value with regard to response to chemother-
py.
To be able to predict the efﬁcacy of induction chemotherapy and
hus reduce toxicity, biomolecular and genetic studies are ongoing:
uman papillomavirus (HPV) infection and especially the presence
f protein p53 and mRNA of oncoproteins E6 and E7 in oropharyn-
eal squamous cell carcinoma seem to be factors of good prognosis
nd good response to radiochemotherapy. In France, however,
PV infection is found in only 11.5–26% of cases of HNSCC [14].
RCC1 gene expression and DPD (dihydropyrimidin dehydroge-
ase) cyclin D1 mutations [15,16] also offer interesting possibilities.
here are, however, no validated biomolecular or genetic tests in
urrent use.
able 3
ET-CT data in chemotherapy responders and non-responders.
Patient group Patients with good chemotherapy response 
Difference in SUV between 2
PET-CT examinations (%)
Difference in hypermetabolic
volume between 2 PET-CT
examinations (%)
0 0 
16.2 0 
16.7 38.7 
23.9 55.4 
32.9 23.3 
50  77.3 
49  56.1 
57.5 45.7 
61.8 53.6
66.2 60.9
67.4 60.3
76.9 80.5
83.4 100
Mean ± SD 46.3 ± 25.03 50.1 ± 28.2 to induction chemotherapy.
In this context, PET-CT offers an interesting predictive cri-
terion for induction chemotherapy response: SUVmax reﬂects
tumor metabolic activity during induction chemotherapy and can
detect changes in tumor metabolism even ahead of morphologic
changes, and without the need for biopsy or surgery. Accord-
ing to the present preliminary results, a reduction of more than
30% in SUVmax in locally advanced HNSCC is predictive of good
response to chemotherapy (P = 0.04). To the best of our knowl-
edge, there have been few studies of PET-CT as a predictor of
induction chemotherapy response in HNSCC [17–19]. In 2005, Yen
et al. demonstrated efﬁcacy in predicting nasopharyngeal tumor
response: only 1 out of 25 responders experienced recurrence,
versus 15 out of 27 non-responders [18]. In 2012, Kikuchi and
Abgral also demonstrated the role of PET-CT in assessing induction
chemotherapy response in HNSCC. Discrepancies between these
two studies, however, raise the issue of the SUVmax reduction
threshold deﬁning tumor response: 55% for Kikuchi [17], but 25%
for Abgral [19]. In gastric and esophageal carcinoma, many studies
Patients with poor chemotherapy response
Difference in SUV between 2
PET-CT examinations (%)
Difference in hypermetabolic
volume between 2 PET-CT
examinations (%)
0 0
12 0
15.9 57.2
17.9 73.6
21.2 57.3
34 86
35 47
37 20.4
21.6 ± 12.96 42.6 ± 32.5
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juvant chemotherapy is a predictor of histopathologic response in patients withM.  Gavid et al. / European Annals of Otorhinola
ave reported a predictive role for PET-CT, with positive predic-
ive values ranging from 77% to 93% and negative predictive values
rom 83% to 95% [9–11]; these studies reported SUVmax reductions
f 30–35% to be predictive of good (> 70%) chemotherapy response.
he present preliminary results agree on this cut-off value. More
han 30% reduction in SUVmax was observed in 3 non-responders:
mage analysis in these cases, however, on the one hand found
hat SUVmax reduction was no greater than 30–40%, and more-
ver that the lesions in question were very voluminous and highly
ecrotic. PET-CT results are thus to be interpreted with caution in
arge tumors. A larger sample would probably conﬁrm this ﬁnding,
nd new criteria taking account of both SUVmax and volume are
robably required for precise assessment of treatment response on
ET-CT.
PET-CT has also been compared with conventional imaging:
n several studies, CT and MRI  were found to be less informative
han [18F]-FDG PET-CT [20]. In 2009, Chepeha et al. showed PET-CT
o be in “substantial” agreement with endoscopy ( = 0.62), com-
ared to merely “fair” agreement for CT ( = 0.4) for the assessment
f chemotherapy response in oropharyngeal carcinoma. Another
tudy, of 19 HNSCC patients, found a signiﬁcant difference in
UVmax reduction after chemotherapy between responders (82%)
nd non-responders (32%; P = 0.01); the same study reported a
on-signiﬁcant difference in tumor volume reduction on CT (80%
nd 41%, respectively; P = 0.09) [21]. MRI  led to the same conclu-
ions: > 55% reduction in SUVmax between diagnosis of HNSCC
nd end of chemotherapy was signiﬁcantly predictive of com-
lete response, with 95% speciﬁcity and 86% sensitivity; tumor
olume reduction on MRI, on the other hand, showed no sig-
iﬁcant ﬁndings (P = 0.12) [22]. Likewise, hypermetabolic tumor
olume assessment on the present technique of threshold determi-
ation by predetermined isocontours did not emerge as predictive
f chemotherapy response. Even so, although this ﬁxed threshold
ethod seems unsuited to the analysis of chemotherapy response,
e consider it indispensable to evaluate other hypermetabolic vol-
me  thresholding methods, adapted to the individual patient, with
ariable SUV isocontours. Determining a reliable hypermetabolic
olume on PET-CT during chemotherapy would help optimize
trategy, especially with regard to surgery.
. Conclusion
[18F]-FDG PET-CT is now widely accepted and recommended
or extension assessment in nasopharyngeal carcinoma and pri-
ary adenopathy. Indications in other head and neck tumors
emain a matter of debate, and recommendations are cautious [23],
otably due to practical issues of equipment access; applications
n chemotherapy could revive interest in this attitude. The present
reliminary study demonstrated that the rate of early reduction in
UVmax exceeding 30% during induction chemotherapy differed
igniﬁcantly between responders and non-responders. A larger
cale study is needed to determine a more reliable cut-off. Other
etabolic volume thresholding techniques should also be assessed.
he use of [18F]-FDG PET-CT could prevent the cumulative toxic-
ty of iterative chemotherapy in relatively non-responsive subjects,
ho could beneﬁt from earlier screening to receive adapted treat-
ent more promptly.isclosure of interest
The authors declare that they have no conﬂicts of interest con-
erning this article.
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